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Abstract
Background: Unlike CD4+ T cells, HIV-1 infected macrophages exhibit extended life span even
upon stress, consistent with their in vivo role as long-lived HIV-1 reservoirs.
Results: Here, we demonstrate that PI3K/Akt inhibitors, including clinically available Miltefosine,
dramatically reduced HIV-1 production from long-living virus-infected macrophages. These PI3K/
Akt inhibitors hyper-sensitize infected macrophages to extracellular stresses that they are normally
exposed to, and eventually lead to cell death of infected macrophages without harming uninfected
cells. Based on the data from these Akt inhibitors, we were able to further investigate how HIV-1
infection utilizes the PI3K/Akt pathway to establish the cytoprotective effect of HIV-1 infection,
which extends the lifespan of infected macrophages, a key viral reservoir. First, we found that HIV-
1 infection activates the well characterized pro-survival PI3K/Akt pathway in primary human
macrophages, as reflected by decreased PTEN protein expression and increased Akt kinase activity.
Interestingly, the expression of HIV-1 or SIV Tat is sufficient to mediate this cytoprotective effect,
which is dependent on the basic domain of Tat – a region that has previously been shown to bind
p53. Next, we observed that this interaction appears to contribute to the downregulation of PTEN
expression, since HIV-1 Tat was found to compete with PTEN for p53 binding; this is known to
result in p53 destabilization, with a consequent reduction in PTEN protein production.
Conclusion: Since HIV-1 infected macrophages display highly elevated Akt activity, our results
collectively show that PI3K/Akt inhibitors may be a novel therapy for interfering with the
establishment of long-living HIV-1 infected reservoirs.
Introduction
A hallmark of HIV pathogenesis is the loss of CD4+ T cells
in HIV-1 infected patients. Infected CD4+ T cells initially
undergo cell cycle arrest at G2 caused by a viral accessory
protein, Vpr, and eventually cytolysis [1,2]. However, the
cell fate and molecular consequences of non-dividing tar-
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get cells of HIV-1 such as macrophages and microglia are
poorly understood. We recently reported that in contrast
to HIV-1 infected CD4+ T cells, infection in primary
human macrophages and a microglial cell line (CHME5)
leads to an extended life span and elevated survival
against apoptotic stresses [3]. We also showed that in the
HIV-1 transduced CHME-5 microglial cell line, this cyto-
protective phenotype is induced by intracellular expres-
sion of HIV-1 Tat, which plays a primary role in the
transcriptional activation of the HIV-1 LTR [4,5].
HIV-1 infected microglia, brain macrophages, are known
to secrete various toxic products such as the Tat and Enve-
lope (Env) proteins, which lead to the death of neighbor-
ing neurons and eventually HIV-1 associated dementia
(HAD) in the infected host [6-9]. In addition to the secre-
tion of viral proteins, it is known that in the central nerv-
ous system (CNS) HIV-1 infected microglia produce nitric
oxide (NO), which contributes to the establishment of a
highly apoptotic environment in close proximity to
infected microglia [10-12]. Even though non-dividing
HIV-1 target cells are exposed to these toxic conditions
nearby, it has been reported that both microglia and tissue
macrophages continue to produce virus for prolonged
periods of time. Indeed, a number of studies have sug-
gested that these non-dividing HIV-1 target cells serve as
long-living viral reservoirs [13-15].
The PI3K/Akt cell survival pathway has been extensively
studied, and has been recognized as a promising target for
anti-cancer therapies because its activation is a key cellular
event during tumorigenesis [16]. Once PI3K and Akt
kinase are activated upon apoptotic stress, they further
transduce signals to a series of downstream regulators of
cell survival. In its normal state, the PI3K/Akt pathway is
negatively regulated by PTEN (phosphatase tensin
homolog), which converts PIP3 to PIP2 [17]. We recently
observed in our microglial cell line model, that the PI3K
inhibitors wortmannin and LY294002 were able to render
HIV-1 infected CHME5s susceptible to cell death follow-
ing an apoptotic stimulus [3].
In this report, we employed primary human macro-
phages, an important HIV-1 target cell type and viral res-
ervoir, and investigated the specific molecular
mechanisms involved in the modulation of the PI3K/Akt
pathway. Importantly, we provide virological evidence
that supports the application of anti-PI3K/Akt reagents as
a potential anti-HIV-1 strategy to eradicate long-living
HIV-1 infected human macrophages and to prevent HIV-
1 production from these viral reservoirs.
Results
PI3K/Akt inhibitors reduce HIV-1 production from infected 
primary human macrophages
We previously reported that HIV-1 infection of primary
human macrophages and the CHME-5 microglial cell line
results in a cytoprotective effect. The prolonged cell sur-
vival of HIV-1 infected human macrophages may there-
fore contribute to the continuous production of HIV-1
progeny from these cells. In an attempt to target the cellu-
lar signaling mechanism associated with the increased
survival of HIV-1 infected macrophage, we tested whether
treatment of HIV-1 infected human macrophages with
PI3K/Akt inhibitors could reduce virus production and
cell survival. For this test, we employed primary human
macrophages and the M-tropic HIV-1 strain, YU-2. First,
primary human macrophages were infected with either
infectious or heat-inactivated YU-2. To mimic the stressful
environment that infected cells are exposed to during
HIV-1 infection, human macrophages were treated with
SNP, which generates cytotoxic nitric oxide (NO), a com-
pound known to be highly elevated in HIV-infected cells.
Three days later, cells were treated with either media
alone, SNP alone, a PI3K/Akt inhibitor alone or a mixture
of SNP and a PI3K/Akt inhibitor. To inhibit Akt, two com-
mercially available inhibitors, Akt inhibitor IV and VIII
(Calbiochem), and a clinically available Akt inhibitor,
Miltefosine, approved for treatment of breast cancer were
used. In addition, we also employed a broad PI3K inhibi-
tor, wortmannin, for inhibition of the PI3K/Akt pathway.
Following treatment as described above, viral production
was then monitored for 12 days by p24 ELISA. In order to
maintain constant cellular stress, inhibitors and SNP were
replenished every 3 days. As shown in Figures 1A–D, SNP
treatment alone did not significantly alter viral produc-
tion as compared to media alone. This indicates that the
HIV-1 infected macrophages were able to produce viral
particles continuously even after 12 days of constant NO
stress. Some studies have actually reported an increase in
viral production following treatment with SNP [18,19].
However, this may be a concentration dependent effect
since a higher concentration of SNP was used in our exper-
iments to induce a stressful environment. Importantly,
however, we did not observe a drastic decrease in viral
production following treatment of infected macrophages
with SNP alone. In addition, treatment with either wort-
mannin or the Akt inhibitors alone did not significantly
reduce virus production in infected macrophages (Figures
1A–D). However, upon treatment with both SNP and
wortmannin, Akt inhibitor IV, Akt inhibitor VIII or Milte-
fosine (Figure 1A–D), viral production was significantly
reduced. Also, as denoted by the asterisks in Figures 1B–
D, viral p24 levels were undetectable at various time
points post-treatment with both the Akt inhibitor and
SNP.Retrovirology 2008, 5:11 http://www.retrovirology.com/content/5/1/11
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Since the Akt pathway is a well-characterized pathway for
cell survival and HIV-1 infected macrophages exhibit an
enhanced survival phenotype, we next tested whether the
delayed viral production following exposure to Akt inhib-
itor and stress (SNP) was related to the induction of cell
death in HIV-1 infected macrophages. For this test, we
quantified cell death under four experimental conditions
using the Live/Dead assay (Figure 1E). This assay uses flu-
orescent dyes which distinguish live cells (green) from
dead cells (red) on the basis of intracellular esterase activ-
ity (viable) and incorporation of the ethidium
homodimer (nonviable). As expected, treatment with
either SNP or either of the PI3K/Akt inhibitors alone did
not induce significant amounts of cell death in infected
macrophages. However, HIV-1 infected macrophages
exposed to both SNP and the PI3K/Akt inhibitors clearly
displayed a high percentage of cell death (as shown by the
extensive red staining in Figure 1E; results for wortman-
nin, Akt inhibitor VIII and Miltefosine were similar; data
not shown). Macrophages treated with heat-inactivated
YU-2 underwent high levels of cell death following SNP
treatment and combined treatment with inhibitor and
Treatment of HIV-infected macrophages with PI3K/Akt inhibitors reduces HIV-1 production and induces cell death Figure 1
Treatment of HIV-infected macrophages with PI3K/Akt inhibitors reduces HIV-1 production and induces cell 
death. Primary human macrophages were infected with HIV-1 YU-2 and either left untreated (media only) or were treated 
with one of four different PI3K/Akt kinase inhibitors in the presence or absence of stress (SNP, 1 mM): (A) the PI3K inhibitor 
wortmannin (100 nM), (B) Akt inhibitor IV (200 nM), (C) Akt inhibitor VIII (105 nM) or (D) Miltefosine 5 μM. Viral superna-
tants were collected every 3 days for 12 days and supernatants were analyzed using the HIV-1 p24 EIA. Asterisks denote unde-
tectable p24 levels. (E) On day 12, YU2-infected macrophages were analyzed for cell viability using the live/dead assay. Viable 
cells are green; dead cells are red. Results are representative of 5 independent, triplicate experiments using cells obtained from 
multiple blood donors. BF: Bright field. Merge: overlay of red and green fluorescence. The average ± SD percentage of dead 
cells is also shown.
BF
Merge
-  +                   -  +
-  -  +                   +
SNP :
Akt IV:
HIV-1 YU-2 infected macrophages
0.2% ± 0.7    2.3% ± 2.1     1.5% ± 0.7    98.3% ± 5.2Retrovirology 2008, 5:11 http://www.retrovirology.com/content/5/1/11
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SNP, further supporting our observation of an extended
survival phenotype in HIV-1 infected macrophages (data
shown in previous manuscript, [3]). The percentage of cell
death induced under each condition is shown below the
panel (Figure 1E). These data suggest that the decrease in
viral production is secondary to the induction of cell
death, following exposure to PI3K/Akt inhibitors.
HIV-1 infection reduces PTEN levels in primary human 
macrophages
Based on the observed potential antiviral activity of the
PI3K/Akt inhibitors in primary human macrophages as
well as the previous data obtained from the CHME5 cell
line [3], we sought to discover the specific molecular
mechanisms associated with the cytoprotective effect of
HIV-1 infection in human primary macrophages. First, we
began to examine various signaling components of this
survival pathway to better understand how HIV-1 infected
macrophages exhibit prolonged survival and how the
inhibition of Akt can lead to the induction of cell death in
this viral reservoir. We previously reported that HIV-1
infection leads to extended survival in primary human
macrophages and CHME5 microglial cells using both
infectious M-tropic HIV-1 YU-2 and an Env and Nef
deleted GFP expressing HIV-1 vector (HIV-GFP). Interest-
ingly, CHME5 cells transduced with the HIV-GFP vector,
displayed reduced levels of PTEN, a key cellular PI3K/Akt
antagonist, compared to CHME5 cells incubated with
heat-inactivated vector. It has been described in a number
of human cancers that genetic inhibition of PTEN
enhances cell survival by facilitating the activation of the
PI3K/Akt pathway [17,20-22]. As a result, we hypothe-
sized that PTEN could be targeted by HIV-1 and that inter-
ference with PTEN may play a role in the cytoprotective
effect exerted in virus-infected macrophages. Therefore,
we tested whether HIV-1 infection also reduces the level of
PTEN protein in primary human macrophages, which are
a key reservoir for HIV-1. Human macrophages were
either infected with M-tropic HIV-1 YU-2 (MOI 40) or
transduced with HIV-GFP (MOI 40) using heat-inacti-
vated virus or vector as a control. The transduction effi-
ciency was measured by GFP expression (Figure 2A). Cell
lysates were prepared 48 hours post-transduction and the
level of PTEN protein was measured by Western blotting
using β-tubulin as a loading control (Figures 2B and 2C).
As shown in Figure 2B, macrophages infected with HIV-1
YU-2 exhibited drastically reduced levels of PTEN protein,
displaying approximately 20% of the PTEN level detected
in control macrophages. Similarly, HIV-GFP transduced
macrophages also exhibited a reduction in PTEN levels to
about 40% of the control (Figure 2C), which is very simi-
lar to that observed during oncogenic cellular transforma-
tion and activation of the PI3K survival pathway
[3,23,24].
We also examined PTEN mRNA levels following transduc-
tion of our pseudotyped HIV-GFP vector in macrophage
by reverse transcriptase PCR (RT-PCR). As shown in Figure
2D, pseudotyped HIV vector-transduced macrophages
displayed drastically decreased levels of mRNA compared
to the heat-inactivated vector control. The observed
HIV-1 expression reduces PTEN levels in primary human  macrophages Figure 2
HIV-1 expression reduces PTEN levels in primary 
human macrophages. (A) Images of primary macrophages 
transduced with HIV vector expressing HIV-1 proteins and 
EGFP (+) or heat-inactivated vector (-). Levels of PTEN pro-
tein in YU-2 infected macrophage (B) and HIV vector-trans-
duced macrophages (C) as determined by Western blotting. 
Ratios of PTEN normalized by β-tubulin levels are shown. 
(D) Reverse transcriptase PCR analysis of PTEN mRNA lev-
els following transduction of macrophage with HIV vector 
(+) or treatment with heat-inactivated vector (-). M: 100 bp 
size marker. β-tubulin and β-Actin were used for loading 
controls in the Western analysis and RT-PCR, respectively.
(A)
(B)
(C)
(D)
HIV YU-2         - +
PTEN
ȕ-tubulin
Ratio:                1x         0.2x
HIV-GFP          - +
PTEN
ȕ-tubulin
Ratio:                1x         0.4x
HIV-GFP:  M       - +
200bp—
200bp—
PTEN
ȕ-Actin
Macrophages
Macrophages
Macrophages
HIV-GFP              - +Retrovirology 2008, 5:11 http://www.retrovirology.com/content/5/1/11
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decrease in mRNA was more pronounced than the
decrease in PTEN protein levels. This is probably because
the half life of endogenous PTEN protein is relatively long
at about 30 hours [25]. Collectively, these data demon-
strate that the cytoprotective effect in macrophages upon
infection with HIV-1 YU-2 or transduction with HIV-GFP
is likely due to the downregulation of PTEN mRNA and
protein levels, which can facilitate the activation of the
PI3K/Akt survival pathway.
HIV-1 infection promotes recruitment of Akt to the plasma 
membrane via its PH domain and results in increased Akt 
kinase activity in primary human macrophages
The PTEN phosphatase normally converts PIP3 to PIP2.
During the activation of the cell survival pathway, high
levels of PIP3 lead to the recruitment of the Akt kinase to
the plasma membrane by binding to the PH domain of
Akt. Therefore, we investigated the effect of HIV-1 infec-
tion on the membrane recruitment of Akt. For this, we
employed an adenoviral vector that expresses an EGFP-PH
fusion protein, in which the PH domain of Akt was fused
to the C-terminus of EGFP (Ad.CMV-EGFP-PHAkt). In
order to detect the localization of PH Akt during HIV-1
infection, we first infected primary human macrophages
with HIV-1 YU-2 and transduced these infected cells 48
hours later with Ad.CMV-EGFP-PHAkt. As shown in Fig-
ure 3A, macrophages treated with heat-inactivated HIV-1
displayed diffuse localization of the PH domain through-
out the cell. In contrast, HIV-1 YU-2 infection resulted in
a distinct localization of EGFP-PHAkt to the plasma mem-
brane. This membrane localization is typically observed
following treatment with epidermal growth factor (EGF),
which is known to activate the PI3K/Akt pathway [26,27].
Interestingly, we also found that treatment of HIV-1
infected macrophages with the Akt inhibitor Miltefosine
inhibited the recruitment of PH-AktGFP to the plasma
membrane (Figure 3A). Since Miltefosine inhibits Akt
through mimicry of the PH domain, it is likely that Milte-
fosine binds to PIP3, blocking the recruitment of PH-Akt
to the membrane. The percentage of macrophages in
which PH domain membrane recruitment was observed is
shown below panel 3A. These results suggest that HIV-1
infection in macrophages induces plasma membrane
recruitment of Akt which can be reversed using Miltefo-
sine, and our results above suggest that this is likely due to
the reduced levels of PTEN expression.
Since plasma membrane recruitment of Akt kinase typi-
cally results in increased phosphorylation and activation
of Akt, we hypothesized that HIV-1 infection might lead
to an increase in Akt kinase activity. Once phosphorylated
and activated, the Akt kinase phosphorylates a series of
downstream signals including GSK3β [28-31]. To test our
hypothesis, we prepared cell lysates from HIV-GFP trans-
duced macrophages and employed an Akt kinase activity
assay which uses active Akt kinase from cell lysates to
phosphorylate GSK3β substrate. As shown in Figure 3B,
macrophages transduced with HIV-GFP displayed an
approximately 40-fold increase in Akt kinase activity over
the cells treated with heat-inactivated vector.
We also tested Akt activity in the CHME5 cell line (Figure
3B), and similar results were obtained although the
increase in kinase activity was substantially less, due to a
HIV-1 infection promotes membrane recruitment of Akt's  PH domain, resulting in increased Akt activity Figure 3
HIV-1 infection promotes membrane recruitment of 
Akt's PH domain, resulting in increased Akt activity. 
(A) Primary human macrophages were sequentially infected 
with M-tropic HIV-1 YU-2 and Ad.CMV-EGFP-PHAkt 
expressing the PH domain of Akt, and localization of the PH 
domain of Akt was assessed by fluorescence microscopy. 
Heat inactivated YU-2 was used as a negative control, and 
treatment with epidermal growth factor (EGF) was used as a 
positive control for Akt activation. HIV-1 infected macro-
phages were treated with 10 μM Miltefosine (Milt.) for inhibi-
tion of Akt. BF: bright field. GFP: green fluorescent protein. 
Inset: High magnification images of representative cells. The 
percentage of membrane localized PH-Akt is shown with the 
SD from three independent experiments. (B) Assay for Akt 
kinase activity. Macrophage and CHME5 cells were trans-
duced with HIV vector and lysed. Using these lysates, an Akt 
kinase activity assay was performed using GSK3β as a sub-
strate. Western blots of phospho-GSK3β (GSK3β-P) and α-
Tubulin (loading control) are shown along with the fold 
induction of Akt kinase activity relative to control. Fold 
increase of Akt kinase activity is also shown. The error bars 
denote the SD from three independent experiments.
HIV-GFP:             -  +            -  +
GSK3ȕ-P
Fold increase:   1x      >40x         1x        5x
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high level of basal Akt activity. Interestingly, pre-treat-
ment of vector-transduced CHME5 cells with a potent Akt
kinase inhibitor, Akt inhibitor IV [32], reduced Akt kinase
activity to a basal level similar to that observed in cells
treated with heat-inactivated vector (Figure 3B). This con-
firms that the HIV-1 induced increase in survival of both
primary macrophages as well as CHME5 cells is likely a
result of increased Akt kinase activity. Importantly, this
data also supports that the decrease of HIV-1 production
by inhibitor treatment, which was observed in Figure 1, is
likely due to induction of cell death via inhibition of the
Akt survival pathway
HIV-1 Tat competes with PTEN for binding to p53
Next, we further tested the molecular mechanisms of the
virological factor involved in the HIV-1 induced long-
term survival of macrophages. It has been known that
HIV-1 Tat protein directly interacts with the C-terminal
region of p53 [33,34], but the virological role of this inter-
action remains speculative. We recently reported that HIV-
1 infection and Tat expression leads to the reduction of
the transcriptional activator function of p53 [3]. Interest-
ingly, like Tat, PTEN also physically binds to the C-termi-
nal region of p53 and this interaction stabilizes p53 [35].
Since p53 is a key transcriptional activator of PTEN, the
stabilization of p53 through PTEN binding enhances the
cellular levels of PTEN which in turn leads to repression of
the PI3K/Akt pathway in normal cells [17]. Based on these
observations, we proposed a possible mechanistic circuit
of the cytoprotective effect exerted by HIV-1 infection and
intracellular Tat protein (Figure 4A): the decrease in PTEN
levels observed during HIV-1 infection and Tat expression
may result from the possible destabilization of p53,
caused by the direct binding of intracellular Tat to p53.
This direct interaction could prevent PTEN from binding
to the C-terminal region of p53.
To test this, we performed an in vitro binding assay based
on the hypothesized competition between Tat and PTEN
for binding to p53 (Figure 4B). p53-containing cell lysates
were incubated for a defined length of time with either an
irrelevant control protein (BSA) or full-length Tat (101
amino acids) to allow binding. Each lysate was then incu-
bated with normalized amounts of PTEN expressing cell
lysates (10 μg). p53 complexes were collected by FLAG-tag
immunoprecipitation and examined by Western blot
analysis using antibodies directed against the C-terminal
V5-tag of PTEN. As seen in Figure 4B, the binding of PTEN
to p53 was drastically reduced following incubation with
Tat, compared to the BSA control. Instead of using puri-
fied tat protein, we could have co-expressed Tat in CHME5
cells. However, since intracellular Tat can decrease p53
levels, this may make it technically difficult to pull down
detectable levels of p53. These data support our model cir-
cuit in which intracellular Tat prevents PTEN from bind-
ing to p53 by interacting with the p53 C-terminal domain.
This molecular competition event may facilitate the acti-
vation of the PI3K/Akt survival pathway in HIV-1 infected
macrophages.
The Basic domain of Tat is involved in the cytoprotective 
effect induced by HIV-1 Tat in primary human 
macrophages
Next, we attempted to identify the domain(s) of Tat pro-
tein that is/are responsible for the cytoprotective effect.
Here, two highly conserved functional domains of Tat
protein were investigated: the cysteine rich domain, a
Binding of HIV-1 Tat to p53 decreases levels of PTEN Figure 4
Binding of HIV-1 Tat to p53 decreases levels of 
PTEN. (A) Proposed mechanistic circuit for intracellular 
HIV-1 Tat: HIV-1 Tat may increase cell survival by preventing 
PTEN from binding to p53. Binding of HIV-1 Tat to p53 may 
result in reduced levels of both p53 by destabilization and 
PTEN by downregulation of PTEN expression. (B) In vitro 
binding assay: Lysates containing p53-FLAG were incubated 
with BSA (control) or HIV-1 Tat protein and then mixed 
with lysate containing PTEN V5-tag. Proteins bound to p53 
were immunoprecipitated using anti-FLAG immobilized anti-
body and analyzed for PTEN-V5 tag levels by Western blot-
ting. Ratios of PTEN-V5 levels normalized by p53-FLAG 
levels are shown.
BSA  Tat
PTEN
p53
Fold decrease:   1x     5x      
PTEN
p53
PTEN
Tat
p53
Decrease of p53 level
(degradation?)
Downregulation of
PTEN expression
HIV-1 infection (A)
(B)
Į-V5 tag
Į-FLAG
IP:FLAGRetrovirology 2008, 5:11 http://www.retrovirology.com/content/5/1/11
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domain required for the transactivation activity of HIV-1
Tat [36,37], and the basic domain, which is involved in
the cellular uptake, nuclear localization, and transcrip-
tional transactivator functions of Tat [36,38-40] (see Fig-
ure 6A for amino acid sequences).
Since the interaction between PTEN and p53 seem to be
important in the extended survival phenotype and
because the binding of Tat to p53 occurs through its basic
domain, we first constructed an HIV-GFP vector contain-
ing the R49Q/K50E mutations in the basic domain of Tat
(HIV-Tat 49/50). The HIV-Tat 49/50 mutant vector was
able to transduce macrophages, indicating that the Tat 49/
50 mutant still harbors the transcription activator func-
tion for activation of the HIV LTR (Figure 5A). Primary
human macrophages were transduced with either a
wildtype HIV vector or the HIV-Tat 49/50 vector contain-
ing the basic domain mutations. For the induction of cell
death, transduced macrophages were either left untreated
or were treated for 24 hours with sodium nitroprusside
(SNP), an NO donor. To monitor cell death we applied
the Live/Dead assay, which was described earlier. As
shown in Figure 5A, macrophages transduced with either
the wildtype or mutant HIV vector alone (without SNP)
did not undergo cell death. However, following treatment
with SNP, macrophages expressing the Tat 49/50 mutant
displayed a greatly increased level of cell death (72%) as
shown by the presence of yellow cells (red/green merge)
while the wildtype vector-transduced cells exhibited little
to no cell death (Figure 5A). Macrophages treated with
heat-inactivated vector underwent efficient cell death fol-
lowing SNP treatment as described previously [3]. There-
fore, these data confirm that the basic domain of Tat plays
a role in the cytoprotective effect exerted by HIV-1 infec-
tion and intracellular HIV-1 Tat.
Next, we performed similar experiments using CHME5
cell sublines expressing either wildtype or one of two
mutant Tat constructs, the basic domain mutant R49Q/
K50E or the transactivation mutant C21G (cysteine-rich
domain: see Figure 6A). As expected, the C21G Tat mutant
exhibited a defect in transactivator function while the con-
struct harboring the basic domain mutation failed to
decrease p53 activity (data not shown). Importantly, the
basic domain mutant retained transactivation activity
similar to wildtype Tat (data not shown). The alterations
in p53 activity following expression of Tat 49/50 could be
due to the abrogation of the interaction between p53 and
Tat, since this binding is known to occur through the basic
domain [33]. Next, we tested the survival ability of the
CHME5 sublines (wild type and mutant) by exposing cells
to  E. coli lipopolysaccharide (LPS) and cycloheximide
(CHX), and analyzing for the induction of cell death. As
shown in Figure 5B, the C21G Tat mutant was still able to
exert the cytoprotective effect of wildtype Tat in CHME5
cells while the R49Q/K50E basic domain mutant Tat
failed to protect CHME5 cells from the apoptotic stress of
LPS/CHX treatment.
We further tested the effect of these Tat mutants on cellu-
lar PTEN levels. For this, CHME5 sublines stably trans-
The Basic domain of Tat is involved in the cytoprotective  effect of HIV-1 Tat Figure 5
The Basic domain of Tat is involved in the cytopro-
tective effect of HIV-1 Tat. (A) Primary human macro-
phages were transduced with either HIV-GFP wt vector or 
HIV-GFP Tat 49/50 vector and treated with SNP 1mM for 24 
hours. Cell death was then analyzed using a vital dye (red 
cells = dead). Transduced cells are shown in green (GFP+) 
while transduced/dead cells are shown in yellow (red+green 
merge; numbers reflect the % yellow cells in ~200 green 
cells). The average percentage of cell death and the standard 
deviation between three independent experiments in tripli-
cate is shown. Luciferase assay results for fold activation of 
the HIV-1 LTR for the wildtype and the Tat basic domain 
mutant vectors are also shown. BF: bright field. (B) CHME5 
sublines expressing wildtype or mutant HIV-1 Tat proteins 
were exposed to LPS/CHX for 24 hours and analyzed for via-
bility using the trypan blue assay. Results are shown as per-
cent cell death. (C) CHME5 sublines expressing wildtype or 
mutant Tat CHME5 sublines were lysed and analyzed for 
PTEN protein levels by Western blot. Normalized expres-
sion levels of PTEN (relative to α-tubulin) are shown.
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fected with plasmids encoding pcDNA3.1, wild type,
C21G or R49Q/K50E Tat protein were analyzed for PTEN
expression by Western blotting. Levels of PTEN protein
were normalized by α-tubulin protein levels. As shown in
Figure 5C, CHME5 cells expressing the R49Q/K50E Tat
mutant failed to decrease PTEN protein levels, while
CHME5 cells expressing the C21G Tat mutant displayed
reduced levels of PTEN similar to wildtype Tat. These data
are consistent with the cytoprotective phenotypes of the
cells expressing these mutants (Figure 5B). Together, these
data suggest that mutations in the Tat basic domain may
alter binding of HIV-1 Tat to p53, resulting in increased
PTEN levels and consequently an increased incidence of
cell death.
SIV Tat also mediates a cytoprotective effect
SIV and HIV Tat contain a stretch of conserved cysteine
residues in the transactivation domain as well as a region
rich in basic residues, as shown in the sequence compari-
son of the cysteine rich and basic domains of HIV-1 (YU-
2), SIVmac239 and SIVPBJ Tat proteins (Figure 6A). There-
fore, we tested whether the expression of SIV Tat could
also induce extended survival of CHME5 cells. A plasmid
expressing either the first exon of HIV-1 Tat (psvTat72:
[41]) or SIVPBJ Tat was transfected into CHME5 cells. We
also co-transfected a GFP expression plasmid to identify
transfected cells expressing Tat. The transfected cells were
exposed to LPS/CHX and their survival capability was
monitored with the Live/Dead assay. As shown in Figure
6B, CHME5 cells expressing either psvTat72 or SIVPBJ Tat
(GFP+) displayed enhanced survival as compared to con-
trol cells transfected with pcDNA3.1 and GFP (green). The
percentage of only the transfected, GFP+ cells undergoing
cell death (red) is shown below each panel. These data
suggest that the C-terminal region of Tat encoded in exon
2 of the Tat gene is not required for the cytoprotective
activity of Tat in CHME5 cells. These results also show that
SIVPBJ Tat is capable of exerting a cytoprotective effect in
CHME5 cells, supporting the possibility that Tat's effects
on macrophage/microglial cell survival are conserved
among lentiviruses.
Discussion
In this study, we identified PI3K/Akt inhibitors as a novel
anti-HIV therapy and examined the specific molecular
mechanisms involved in the cytoprotective effect of HIV-
1 infection in primary human macrophages. As summa-
rized in Figure 7, our study revealed that HIV-1 expression
in macrophages triggers a series of key cellular events typ-
ically observed during cell survival activation: PTEN
reduction, membrane localization of Akt and elevated Akt
kinase activity. Interestingly, treatment of HIV-1 trans-
duced macrophages with the Akt inhibitor Miltefosine
was able to reverse the recruitment of PH-Akt to the
plasma membrane and the downstream activation of Akt
kinase (Figure 3). These cellular alterations, together with
the previously reported reduction in p53 activity, mecha-
nistically explain the extended survival phenotype of HIV-
1 infected macrophages under stress conditions. This
increase in survival of HIV-1 infected macrophages is
likely to contribute to viral production and establishment
of macrophages as long-lived viral reservoirs.
Mutational studies revealed a novel cytoprotective role for
the basic domain of Tat protein. We also observed a
decrease in PTEN binding to p53 in the presence of intra-
cellular Tat. Mutations in the basic domain of Tat likely
interfere with the ability of HIV-1 Tat to bind p53, allow-
ing stabilization of p53 by PTEN and increased PTEN lev-
els, resulting in abrogation of the cytoprotective
phenotype in primary macrophages. In addition, we
found that SIV Tat was also capable of protecting CHME5
cells from death. This supports the possibility that Tat's
cytoprotective function may be conserved among HIV-1
and SIV Tat proteins, and that these two lentiviruses may
share a mechanism for promoting the extended survival of
infected macrophages and microglia. Indeed, it is also
known that SIV infected macrophages serve as a long-liv-
SIV Tat also exerts a cytoprotective effect Figure 6
SIV Tat also exerts a cytoprotective effect. (A) 
Sequence comparison of the cysteine-rich and basic domains 
from HIV-1 YU-2, SIV mac239 and SIV PBJ. Numbers indicate 
residues on the first amino acids of the shown sequences. 
Colored residues in HIV-1 Tat were mutated in this study. 
(B) CHME5 cells were cotransfected with a plasmid encod-
ing GFP and constructs expressing the first exon of HIV-1 
Tat (psvTat72), SIV-PBJ Tat, or with an empty plasmid 
(pcDNA3.1) using Lipofectamine. Cells were then treated 
with LPS/CHX and analyzed for cell death. Bright fields (BF) 
and merged (red+green) fields are shown. Transfected cells 
are GFP+ cells (green), dead cells (red). The percentage of 
cell death induced in GFP+, EthD+ cells is shown with the SD 
from three independent experiments.
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20: ACNN-CYCKKCCFHCQVC: HIV-1 YU-2
45: ACYNTCYCKKCCYHCQHC: SIVmac239
52: ACYNKCYCKRCCYHCQHC: SIVPBJ
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48: GRKKRRQRRRP: HIV-1 YU-2
79: SRKRRRTPKKA: SIVmac239
82: QRRRTPKKTKT: SIVPBJ
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ing viral reservoir [42]. Therefore, SIV-infected macaque
models may be promising in further developing Akt
inhibitors as a novel antiviral therapeutic.
Most importantly, we also examined the ability of PI3K/
Akt inhibitors to induce cell death specifically in HIV-1
infected macrophages exposed to SNP stress, which simu-
lates the in vivo local toxic environment. A significant
decrease in HIV-1 production from infected macrophages
was observed upon combined treatment with SNP and
PI3K/Akt inhibitors. This finding suggests that PI3K/Akt
inhibitors may have utility as a potential new anti-HIV
therapy that is able to specifically target non-dividing
HIV-1 target cells such as macrophages, which play impor-
tant roles in pathogenesis as long-lived HIV-1 reservoirs.
Interestingly, infected macrophages treated with SNP or
inhibitor alone did not display any signs of cell death or
decreased viral production, whereas infected macro-
phages treated with both SNP and the PI3K/Akt inhibitors
underwent cell death with little viral production. This
observation indicates that the inhibitory effect of the
PI3K/Akt inhibitors on viral production from infected
macrophages requires a stressed environment-as may
occur in vivo, in association with immune activation and
cytokine production [43].
More interestingly, the Akt inhibitor Miltefosine, which
has undergone multiple clinical trials and has been
approved for treatment of breast cancer in Europe and
parasite infections in other countries, was also able to
inhibit viral production and cell survival in HIV-1 infected
macrophages. In addition, we also found that another Akt
inhibitor, Perifosine, which is also currently in clinical tri-
als, was able to decrease viral production and induce cell
death in HIV-1 infected macrophages (data not shown).
One interesting question is why HIV-1 infected CD4+ T
cells undergo cell death. It is plausible that HIV-1 infec-
tion (and Tat expression) may promote cell cycle progres-
sion in dividing/activated CD4+ T cells. However, in these
infected, dividing CD4+ T cells, due to the strong G2 cell
cycle arresting activity of HIV-1 Vpr, further progression
through the cell cycle and cell survival may be prevented,
resulting in cytolysis [44,45]. Another HIV-1 reservoir cell
type is the HIV-1 infected resting memory CD4+ T cell
[46,47]. It would be interesting to investigate whether
HIV-1 infection also activates the PI3K/Akt pathway in
these cells, and if so, whether treatment with PI3K/Akt
inhibitors results in elimination of these cells.
In addition to the large number of macrophage/microglia
in the toxic environment of the CNS during infection, it
has been reported that many of the cells producing HIV-1
in the lymph nodes, spleen and intestine of infected hosts
are macrophages [48,49]. These tissue macrophages are
also known to persistently produce virus for a long period
of time, serving as viral reservoirs. Therefore, it is possible
that treatment with Akt inhibitors that are unable to cross
the blood brain barrier (BBB) would result in eradication
of these infected tissue macrophages. Interestingly, how-
ever, it was reported that alkyllysophospholipids such as
Miltefosine are able to penetrate the BBB [50-53], which
supports the potential use of Miltefosine to eradicate viral
reservoirs of the CNS.
Conclusion
This study elucidates the molecular and cellular mecha-
nisms involved in the cytoprotective effect of HIV-1 infec-
tion in primary human macrophages and indicates the
PI3K/Akt pathway as a key contributor to this effect. It is
increasingly apparent that many PI3K/Akt inhibitors
under development as anti-cancer therapy are safe and
well-tolerated in both experimental animals and humans
[54-57]. Indeed, several inhibitors including Miltefosine
have been approved for treatment of human cancers. This
further supports the possible use of PI3K/Akt inhibitors
for anti-HIV therapy and targeting of long-lived viral res-
ervoirs.
Mechanistic model for the cytoprotective effect of HIV-1  infection and Tat expression Figure 7
Mechanistic model for the cytoprotective effect of 
HIV-1 infection and Tat expression. A summary of the 
findings induced by HIV-1 infection and intracellular Tat 
expression, including the mechanistic actions leading to acti-
vation of the PI3K/Akt pathway and subsequent long-term 
survival of macrophages, is shown. Observed alterations in 
the signaling pathway induced by HIV-1 infection are shown 
in block arrows. The dotted arrow indicates an alternative 
possible cytoprotective effect caused by p53 downregulation. 
Akt with asterisk denotes the activated/phosphorylated form 
of the protein.
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Methods
Cells, viruses, HIV-1 vectors and plasmids
Primary human monocyte-derived macrophages were iso-
lated from human buffy coats and differentiated as previ-
ously described [58]. The CHME5 microglial cell line was
maintained as described previously [3]. M-tropic HIV-1
YU-2 was prepared using human PBMCs [3], and VSV-G
pseudotyped HIV-1 vectors expressing EGFP and all HIV
proteins except Nef and Env were prepared as described
[58] and used to transduce primary human macrophages.
Vector titers were determined using CHME5 cells, and the
p24 EIA was performed for each vector or virus prepara-
tion following manufacturer's protocol (PerkinElmer).
The plasmid encoding the first exon of Tat, psvTat72, was
obtained from the NIH AIDS reagent program. The p53-
FLAG plasmid constructed by Dr. Thomas Roberts [59]
was purchased from Addgene (plasmid 10838). A plas-
mid encoding the PTEN gene was a generous gift from Dr.
Jim Miller (University of Rochester). Using this plasmid, a
linker sequence followed by the V5 tag sequence was
introduced by PCR. After construction of PTEN-V5 tag, the
tagged gene was inserted into pcDNA3.1+Hygro (Invitro-
gen) using the KpnI and XhoI restriction sites.
EGFP-PHAkt expressing adenovirus vector
The EGFP-PHAkt fusion gene from pEGFP-PHAkt [60]
was cloned into pShuttle-CMV prior to recombination
into pAdEasy (Stratagene). Recombinant adenoviral
stocks (Ad.CMV-EGFP-PHAkt) were then generated fol-
lowing transfection in HEK293A cells using methods pro-
vided by the supplier (Stratagene). The virus was purified
by CsCl density gradient centrifugation and the viral titer
was determined by real-time PCR on a BioRad icycler
(Hercules, CA) using a Taqman probe and primers that
amplified a small portion of the Adenovirus hexon gene
[61].
PHAkt membrane localization
Primary human macrophages (5 × 104 cells) were infected
with HIV-1 YU-2 (MOI = 40) for 48 hours. Heat-inacti-
vated YU-2 was used as a control. Cells were washed with
DPBS and transduced with Ad.CMV-EGFP-PHAkt (MOI =
3000) for 24 hours. Positive control cells were treated
with epidermal growth factor (EGF, Sigma) for 15 min-
utes before fixation with 3% formaldehyde. For inhibition
of membrane localization, infected macrophages were
treated with Miltefosine (10 μM) 24 hours post-infection
for 48 hours prior to fixation. Macrophages were visual-
ized for the localization of the PH domain of Akt by exam-
ining GFP fluorescence on a Leica microscope (200×).
Akt kinase activity assay
Primary human macrophages (1 × 106) and CHME5 (1 ×
106) cells were transduced with pseudotyped HIV-GFP
vector (MOI of 40 for macrophages and MOI of 1 for
CHME5 cells), giving ~95% transduction. CHME5 cells
were treated with Akt inhibitor IV (.2 μM) for 24 hours
following transduction with the HIV-GFP vector where
specified. 48 hours post-transduction, cells were lysed
using ELB lysis buffer before performing the Akt kinase
activity assay (Cell Signaling) as per the manufacturer's
protocol. Following incubation with the GSK3β fusion
protein, 6 × SDS stop buffer was added and samples were
loaded onto an SDS 8% (w/v) polyacrylamide gel and
then transferred to nitrocellulose membrane (Hybond,
Amersham Biosciences). Using the antibodies supplied,
GSK3β-P levels were detected by Western blot analysis.
Protein levels were normalized using β-tubulin as a load-
ing control. Each assay was performed in triplicate.
Reverse transcriptase PCR
Macrophages were transduced with either the HIV-GFP
vector or an adenoviral vector expressing GFP +/- Tat. 24
hours post adenoviral transduction or 5 days post HIV
vector transduction, cells were lysed for RNA isolation.
cDNA was then synthesized from the RNA samples using
the Qiagen cDNA synthesis kit (Qiagen, CA) as per the
manufacturer's protocol. RT-PCR was then performed
using the following primers for PTEN: F primer – 5' TTT-
GAAGACCATAACCCACCA 3'; R primer – 5' CCATA-
GAAATCTAGGGCCTCT 3'. The β-actin RT-PCR was
performed with the primers as previously described [62].
Western blotting
Cell lysates were prepared in ELB buffer supplemented
with protease inhibitors (Sigma) and phosphatase inhibi-
tor cocktail (Sigma) and samples (10–20 μg) were applied
to an SDS 8% (w/v) polyacrylamide gel. The expression of
the proteins of interest was detected by probing with the
PTEN (138G6) rabbit monoclonal antibody (Cell Signal-
ing) or M2 FLAG mouse antibody (Sigma, 1:1000). Don-
key anti-rabbit Ig or sheep anti-mouse Ig (Amersham
Biosciences, 1:5000) for secondary antibody followed by
ECL detection using the SuperSignal West Femto kit
(Pierce). For a loading control, blots were probed for α-
tubulin (Cell Signaling) followed by sheep anti-mouse
IgG (Amersham Biosciences). Expression of the protein of
interest in each sample was normalized to either β-tubulin
or p53-FLAG levels for analysis using ImageJ software
(NIH), and ratios were determined from experiments in
triplicate.
p53 binding competition assay
CHME5 cells were transfected with either a plasmid
encoding p53-FLAG or PTEN-V5 tag. After 24 hours, cells
were lysed in ELB buffer. Following normalization of pro-
tein concentration of each lysate, p53-FLAG-containing
lysate (10 μg) was incubated with Tat101 protein (Xepta-
gen, 2 μg/ml) and allowed to bind for 30 minutes at 4°C
on a rocking platform. Following this incubation, anRetrovirology 2008, 5:11 http://www.retrovirology.com/content/5/1/11
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equal protein amount (10 μg) of PTEN-V5 lysate was
added and allowed to bind for an additional 30 minutes
at 4°C. The combined lysates were then applied to EZview
Red anti-FLAG M2 affinity gel (Sigma) for immunoprecip-
itation as per the manufacturer's protocol. After elution of
the p53 complexes with 6× SDS buffer, lysates were
applied to an SDS 8% (w/v) polyacrylamide gel and West-
ern analysis was performed as described above. PTEN
expression was detected using a mouse anti-V5 tag anti-
body (Serotec, 1:1000) followed by sheep anti-mouse IgG
(Amersham Biosciences, 1:5000). ECL detection was then
performed as described above and the membrane was rep-
robed for p53-FLAG as a loading control. Each binding
ratio was performed in triplicate.
Cell death assays
Sodium nitroprusside (Sigma) was used at 1 mM for treat-
ment of macrophages. The live/dead assay was then per-
formed as previously described [3] and percent cell death
is shown. For analysis of induction of cell death in the
CHME5 Tat and control sublines, cells were exposed to
CHX (10 μg/ml) and E. coli serotype O26:B6 LPS (Sigma)
at a concentration of 50 μg/ml or 100 μg/ml for 24 hours.
For the live/dead assay, cells were cotransfected with a
plasmid encoding GFP and a construct expressing either
SIVPBJ Tat or psvTat72 (NIH AIDS Reagent Program). Fol-
lowing treatment with LPS (50 μg/ml) and CHX (10 μg/
ml), cells were analyzed for cell death using the Live/Dead
Cytotoxicity/Viability assay (Molecular Probes) as per the
manufacturer's protocol. Images were taken at a magnifi-
cation of 200 × 24 h post-treatment using a fluorescence
microscope (Leica). Each assay was performed in tripli-
cate.
Construction of HIV-1 Tat mutants
The control (pcDNA3.1) and wildtype Tat (pTat101)
expressing CHME5 sublines were constructed as previ-
ously described [3]. For creation of the transactivation
mutant C21G, the sequence at amino acids 20/21 was
changed to GCCGGC by site-directed mutagenesis while
amino acids 49 and 50 (Arg and Lys) were changed to
CAGGAG (Glu and Gln) to create the basic domain
mutant. The C21G and 49/50 Tat mutants were then
cloned into the pcDNA3.1+Hygro plasmid (Invitrogen).
To create stably expressing CHME5 sublines, cells were
transfected with the above constructs and selected using
hygromycin for two weeks. The resulting CHME5 sublines
were referred to as C21G (transactivation mutant) and Tat
49/50 (basic domain mutant). Three independent subline
clones were isolated and used for characterization. The
cell lines were tested for transactivation activity using a
luciferase assay measuring activation of the HIV-1 LTR. A
plasmid encoding the HIV-1 LTR promoter region fused
to a luciferase cassette was transfected into the CHME5
cell lines and 24 hours later, cells were lysed and the luci-
ferase assay was performed as previously described [3].
In order to construct the pseudotyped vector system
expressing the Tat 49/50 mutant, the Quickchange II XL
kit (Stratagene) was used. The following primers were
used to target amino acids 49 and 50 of the Tat gene,
changing the AGGAAG sequence to CAGGAG: F primer –
5' GGCATCTCCTATGGCCAGG AGAAGCGGA-
GACAGCG 3'; R primer – 5' CGCTGTCTCCGCTTCTC-
CTGG CCATAGGAGATGCC 3'. The sequence of the
vector was confirmed by sequencing.
Virus production assay
Primary human macrophages were infected with HIV-1
YU-2 (1 × 105 pg). Three days post-infection, cells were
washed with DPBS to eliminate the presence of virus.
After washing, cells were cultured either in media alone,
media containing SNP (1 mM) only, media supple-
mented with the PI3K inhibitor wortmannin (100 nM,
Sigma) or the specific Akt inhibitors IV, VIII (200 nM, 105
nM, Calbiochem) [32] or Miltefosine (5 uM, Cayman
Chemicals) only or a combination of inhibitors and SNP.
Infected macrophages were cultured for 12 days, during
which time viral supernatants were collected and fresh
media with inhibitors or SNP was also added every 3 days.
The p24 levels contained in each viral supernatant sample
at the various time points was monitored using the p24
enzyme-linked immunosorbent assay (Beckman-Coulter)
according to the manufacturer's protocol. Viral produc-
tion was plotted over time and asterisks denote undetect-
able p24 levels. On day 12, cells were analyzed for the
induction of cell death using the live/dead assay as
described above. Bright fields and merged (red + green)
fields are shown. Green cells represent viable cells while
red-stained cells correspond to dead or dying cells. The
average percentage of cell death induced was determined
from three independent experiments and is shown with
the SD.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
PC carried out the studies and drafted the manuscript. BBT
constructed and produced the adenoviral vector used in
the PH domain localization study. CMRMF constructed
the pseudotyped vector encoding the basic domain Tat
mutant. VP, SBM and SD helped with interpretation of
data and revision of the manuscript as well as preparation
of reagents. BK conceived of the study, participated in its
design and coordination and drafted the manuscript. All
authors read and approved the final manuscript.Retrovirology 2008, 5:11 http://www.retrovirology.com/content/5/1/11
Page 12 of 13
(page number not for citation purposes)
Acknowledgements
This study was supported by NIH grants (BK, R01 AI049881; PC, AI064136; 
SD, PO1 MH064570; VP, R01 AI49057; SM, RO1 NS 054578; CM, CNPQ 
fellowship 133328/2006-6 (Brazil)).
References
1. Selliah N, Finkel TH: Biochemical mechanisms of HIV induced
T cell apoptosis.  Cell Death Differ 2001, 8:127-136.
2. Zhao RY, Elder RT: Viral infections and cell cycle G2/M regula-
tion.  Cell Res 2005, 15:143-149.
3. Chugh P, Fan S, Planelles V, Maggirwar SB, Dewhurst S, Kim B: Infec-
tion of human immunodeficiency virus and intracellular viral
Tat protein exert a pro-survival effect in a human microglial
cell line.  J Mol Biol 2007, 366:67-81.
4. Harrich D, Ulich C, Garcia-Martinez LF, Gaynor RB: Tat is required
for efficient HIV-1 reverse transcription.  Embo J 1997,
16:1224-1235.
5. Jeang KT, Berkhout B, Dropulic B: Effects of integration and rep-
lication on transcription of the HIV-1 long terminal repeat.  J
Biol Chem 1993, 268:24940-24949.
6. Mattson MP, Haughey NJ, Nath A: Cell death in HIV dementia.
Cell Death Differ 2005, 12 Suppl 1:893-904.
7. Shi B, Raina J, Lorenzo A, Busciglio J, Gabuzda D: Neuronal apop-
tosis induced by HIV-1 Tat protein and TNF-alpha: potenti-
ation of neurotoxicity mediated by oxidative stress and
implications for HIV-1 dementia.  J Neurovirol 1998, 4:281-290.
8. Singh IN, Goody RJ, Dean C, Ahmad NM, Lutz SE, Knapp PE, Nath A,
Hauser KF: Apoptotic death of striatal neurons induced by
human immunodeficiency virus-1 Tat and gp120: Differential
involvement of caspase-3 and endonuclease G.  J Neurovirol
2004, 10:141-151.
9. Kruman, Nath A, Mattson MP: HIV-1 protein Tat induces apop-
tosis of hippocampal neurons by a mechanism involving cas-
pase activation, calcium overload, and oxidative stress.  Exp
Neurol 1998, 154:276-288.
10. Zhao ML, Kim MO, Morgello S, Lee SC: Expression of inducible
nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1
encephalitis.  J Neuroimmunol 2001, 115:182-191.
11. Polazzi E, Levi G, Minghetti L: Human immunodeficiency virus
type 1 Tat protein stimulates inducible nitric oxide synthase
expression and nitric oxide production in microglial cultures.
J Neuropathol Exp Neurol 1999, 58:825-831.
12. Kan H, Xie Z, Finkel MS: HIV gp120 enhances NO production
by cardiac myocytes through p38 MAP kinase-mediated NF-
kappaB activation.  Am J Physiol Heart Circ Physiol 2000,
279:H3138-43.
13. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner
R: Cells of the central nervous system as targets and reser-
voirs of the human immunodeficiency virus.  Virus Res 2005,
111:194-213.
14. Lambotte O, Deiva K, Tardieu M: HIV-1 persistence, viral reser-
voir, and the central nervous system in the HAART era.  Brain
Pathol 2003, 13:95-103.
15. Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, Balestra E,
Calio R, Perno CF: Long-term survival and virus production in
human primary macrophages infected by human immuno-
deficiency virus.  J Med Virol 2002, 68:479-488.
16. El-Deiry WS: Akt takes centre stage in cell-cycle deregulation.
Nat Cell Biol 2001, 3:E71-3.
17. Osaki M, Oshimura M, Ito H: PI3K-Akt pathway: its functions
and alterations in human cancer.  Apoptosis 2004, 9:667-676.
18. Blond D, Raoul H, Le Grand R, Dormont D: Nitric oxide synthesis
enhances human immunodeficiency virus replication in pri-
mary human macrophages.  J Virol 2000, 74:8904-8912.
19. Jimenez JL, Gonzalez-Nicolas J, Alvarez S, Fresno M, Munoz-Fernan-
dez MA: Regulation of human immunodeficiency virus type 1
replication in human T lymphocytes by nitric oxide.  J Virol
2001, 75:4655-4663.
20. Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A,
Govindan R, McLeod HL: PTEN and phosphorylated AKT
expression and prognosis in early- and late-stage non-small
cell lung cancer.  Oncol Rep 2007, 17:853-857.
21. Hay N: The Akt-mTOR tango and its relevance to cancer.
Cancer Cell 2005, 8:179-183.
22. Newton HB: Molecular neuro-oncology and development of
targeted therapeutic strategies for brain tumors. Part 2:
PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
Expert Rev Anticancer Ther 2004, 4:105-128.
23. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT,
Reddy SA, Sabapathy K: c-Jun promotes cellular survival by sup-
pression of PTEN.  Cell Death Differ 2007, 14:218-229.
24. Zhang H, Liu R, Wang R, Hong S, Xu H, Zhang YW: Presenilins reg-
ulate the cellular level of the tumor suppressor PTEN.  Neu-
robiol Aging 2007.
25. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB: The tumor sup-
pressor PTEN is necessary for human Sprouty 2-mediated
inhibition of cell proliferation.  J Biol Chem 2006, 281:4816-4822.
26. Henson ES, Gibson SB: Surviving cell death through epidermal
growth factor (EGF) signal transduction pathways: implica-
tions for cancer therapy.  Cell Signal 2006, 18:2089-2097.
27. Lin J, Adam RM, Santiestevan E, Freeman MR: The phosphatidyli-
nositol 3'-kinase pathway is a dominant growth factor-acti-
vated cell survival pathway in LNCaP human prostate
carcinoma cells.  Cancer Res 1999, 59:2891-2897.
28. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burger-
ing BM: Essential role for protein kinase B (PKB) in insulin-
induced glycogen synthase kinase 3 inactivation. Characteri-
zation of dominant-negative mutant of PKB.  J Biol Chem 1998,
273:13150-13156.
29. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Inter-
leukin-3-induced phosphorylation of BAD through the pro-
tein kinase Akt.  Science 1997, 278:687-689.
30. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC: Cytoplasmic
localization of p21Cip1/WAF1 by Akt-induced phosphoryla-
tion in HER-2/neu-overexpressing cells.  Nat Cell Biol 2001,
3:245-252.
31. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC: HER-2/neu
induces p53 ubiquitination via Akt-mediated MDM2 phos-
phorylation.  Nat Cell Biol 2001, 3:973-982.
32. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ,
Roberts TM, Clardy J, Sellers WR, Silver PA: A chemical genetic
screen identifies inhibitors of regulated nuclear export of a
Forkhead transcription factor in PTEN-deficient tumor cells.
Cancer Cell 2003, 4:463-476.
33. Longo F, Marchetti MA, Castagnoli L, Battaglia PA, Gigliani F: A novel
approach to protein-protein interaction: complex formation
between the p53 tumor suppressor and the HIV Tat pro-
teins.  Biochem Biophys Res Commun 1995, 206:326-334.
34. Ariumi Y, Kaida A, Hatanaka M, Shimotohno K: Functional cross-
talk of HIV-1 Tat with p53 through its C-terminal domain.
Biochem Biophys Res Commun 2001, 287:556-561.
35. Tang Y, Eng C: PTEN autoregulates its expression by stabiliza-
tion of p53 in a phosphatase-independent manner.  Cancer Res
2006, 66:736-742.
36. Ulich C, Dunne A, Parry E, Hooker CW, Gaynor RB, Harrich D:
Functional domains of Tat required for efficient human
immunodeficiency virus type 1 reverse transcription.  J Virol
1999, 73:2499-2508.
37. Kuppuswamy M, Subramanian T, Srinivasan A, Chinnadurai G: Multi-
ple functional domains of Tat, the trans-activator of HIV-1,
defined by mutational analysis.  Nucleic Acids Res 1989,
17:3551-3561.
38. Watson K, Edwards RJ: HIV-1-trans-activating (Tat) protein:
both a target and a tool in therapeutic approaches.  Biochem
Pharmacol 1999, 58:1521-1528.
39. Hauber J, Malim MH, Cullen BR: Mutational analysis of the con-
served basic domain of human immunodeficiency virus tat
protein.  J Virol 1989, 63:1181-1187.
40. Vives E, Brodin P, Lebleu B: A truncated HIV-1 Tat protein basic
domain rapidly translocates through the plasma membrane
and accumulates in the cell nucleus.  J Biol Chem 1997,
272:16010-16017.
41. Subramani S, Mulligan R, Berg P: Expression of the mouse dihy-
drofolate reductase complementary deoxyribonucleic acid
in simian virus 40 vectors.  Mol Cell Biol 1981, 1:854-864.
42. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischof-
berger N, Hirsch V, Martin MA: Macrophage are the principal
reservoir and sustain high virus loads in rhesus macaques
after the depletion of CD4+ T cells by a highly pathogenic
simian immunodeficiency virus/HIV type 1 chimera (SHIV):Retrovirology 2008, 5:11 http://www.retrovirology.com/content/5/1/11
Page 13 of 13
(page number not for citation purposes)
Implications for HIV-1 infections of humans.  Proc Natl Acad Sci
U S A 2001, 98:658-663.
43. Gendelman HE, Skillman DR, Meltzer MS: Interferon alpha (IFN)-
macrophage interactions in human immunodeficiency virus
(HIV) infection: role of IFN in the tempo and progression of
HIV disease.  Int Rev Immunol 1992, 8:43-54.
44. Amini S, Khalili K, Sawaya BE: Effect of HIV-1 Vpr on cell cycle
regulators.  DNA Cell Biol 2004, 23:249-260.
45. Andersen JL, Planelles V: The role of Vpr in HIV-1 pathogenesis.
Curr HIV Res 2005, 3:43-51.
46. Siliciano JD, Siliciano RF: A long-term latent reservoir for HIV-
1: discovery and clinical implications.  J Antimicrob Chemother
2004, 54:6-9.
47. Blankson J, Persaud D, Siliciano RF: Latent reservoirs for HIV-1.
Curr Opin Infect Dis 1999, 12:5-11.
48. Bhoopat L, Rithaporn TS, Khunamornpong S, Bhoopat T, Taylor CR,
Thorner PS: Cell reservoirs in lymph nodes infected with HIV-
1 subtype E differ from subtype B: identification by com-
bined in situ polymerase chain reaction and immunohisto-
chemistry.  Mod Pathol 2006, 19:255-263.
49. Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J,
Lewis G, Kalyanaraman VS, Gallo RC, Racz P: Persistence of HIV-
1 structural proteins and glycoproteins in lymph nodes of
patients under highly active antiretroviral therapy.  Proc Natl
Acad Sci U S A 2005, 102:14807-14812.
50. Olliaro P, Lazdins J, Guhl F: Developments in the treatment of
leishmaniasis and trypanosomiasis.  Expert Opin Emerg Drugs
2002, 7:61-67.
51. Reddy MA, Prasadarao NV, Wass CA, Kim KS: Phosphatidylinosi-
tol 3-kinase activation and interaction with focal adhesion
kinase in Escherichia coli K1 invasion of human brain micro-
vascular endothelial cells.  J Biol Chem 2000, 275:36769-36774.
52. Marschner N, Kotting J, Eibl H, Unger C: Distribution of hexade-
cylphosphocholine and octadecyl-methyl-glycero-3-phos-
phocholine in rat tissues during steady-state treatment.
Cancer Chemother Pharmacol 1992, 31:18-22.
53. Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H,
Lakomek M: Erucylphosphocholine: pharmacokinetics, biodis-
tribution and CNS-accumulation in the rat after intravenous
administration.  Cancer Chemother Pharmacol 1999, 44:484-490.
54. Morgensztern D, McLeod HL: PI3K/Akt/mTOR pathway as a
target for cancer therapy.  Anticancer Drugs 2005, 16:797-803.
55. Momota H, Nerio E, Holland EC: Perifosine inhibits multiple sig-
naling pathways in glial progenitors and cooperates with
temozolomide to arrest cell proliferation in gliomas in vivo.
Cancer Res 2005, 65:7429-7435.
56. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N,
Matthews S, Eisenhauer E: A phase II study of perifosine (D-
21226) in patients with previously untreated metastatic or
locally advanced soft tissue sarcoma: A National Cancer
Institute of Canada Clinical Trials Group trial.  Invest New
Drugs 2006, 24:435-439.
57. Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T,
Belanger K, Smylie M: Phase II study of perifosine in previously
untreated patients with metastatic melanoma.  Invest New
Drugs 2005, 23:569-575.
58. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam
AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S,
Kim B: Macrophage tropism of HIV-1 depends on efficient cel-
lular dNTP utilization by reverse transcriptase.  J Biol Chem
2004, 279:51545-51553.
59. Gjoerup O, Zaveri D, Roberts TM: Induction of p53-independent
apoptosis by simian virus 40 small t antigen.  J Virol 2001,
75:9142-9155.
60. Varnai P, Balla T: Visualization of phosphoinositides that bind
pleckstrin homology domains: calcium- and agonist-induced
dynamic changes and relationship to myo-[3H]inositol-
labeled phosphoinositide pools.  J Cell Biol 1998, 143:501-510.
61. Heim A, Ebnet C, Harste G, Pring-Akerblom P: Rapid and quanti-
tative detection of human adenovirus DNA by real-time
PCR.  J Med Virol 2003, 70:228-239.
62. Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, Dewhurst S,
Maggirwar SB: Functional synergy between CD40 ligand and
HIV-1 Tat contributes to inflammation: implications in HIV
type 1 dementia.  J Immunol 2007, 178:3226-3236.
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral